Dr. David Bostwick stands as a preeminent figure in urologic pathology with over four decades of distinguished service to the medical field. He currently serves as Chief Medical Officer and Laboratory Director at Granger Genetics, CEO of Triopsy Inc., and CEO and General Manager at Rampart Health, demonstrating exceptional leadership across multiple healthcare enterprises. Previously, he held the position of Professor of Pathology and Urology at the Mayo Clinic from 1991 to 1999, where he established himself as a leading authority in diagnostic pathology. His educational foundation includes training at prestigious institutions including the University of Maryland and Stanford University, which prepared him for his groundbreaking contributions to clinical pathology. In 1999, Dr. Bostwick founded Bostwick Laboratories, which has since grown to become the leading urologic pathology practice in the United States.
Internationally recognized as the most sought-after pathologist for second opinions in urologic pathology, Dr. Bostwick has authored 17 books, more than 30 book chapters, and over 500 professional papers that have significantly shaped modern understanding of prostate cancer, bladder cancer, and other urologic diseases. His seminal textbook Urologic Surgical Pathology, first published in 1997 and now in its third edition, remains the definitive reference and bestselling text in the field worldwide. With more than 2000 lectures delivered across the globe, he has profoundly influenced diagnostic standards and practices in urologic pathology. Dr. Bostwick previously served as President of the International Society of Urological Pathology and currently contributes his expertise to the editorial boards of eight major medical journals, establishing him as the authoritative voice in his specialty.
As a leader in the integration of advanced technologies into clinical diagnostics, Dr. Bostwick recently presented on the transformative role of digital pathology and artificial intelligence in improving diagnostic accuracy at the 27th Annual Southwest Prostate Cancer Symposium in October 2024. His research continues to bridge the gap between innovative technological approaches and practical clinical applications, serving as Principal Investigator or Co-Investigator for more than 10 clinical trials that advance precision diagnostics in urologic cancers. Through his leadership at Granger Genetics and collaboration with Chief Scientific Officer Dr. Daniel Hagaman, he is expanding high-quality diagnostic test portfolios to enhance patient outcomes. Dr. Bostwick's enduring commitment to excellence ensures his continued influence in shaping the future of urologic pathology and cancer diagnostics for the next generation of medical professionals.
